Peptide Therapeutics
•41 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (41)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Peptide therapeutics (tirzepatide family) are a core part of Lilly's portfolio.
|
$1.00T |
$1065.49
+0.55%
|
|
ABBV
AbbVie Inc.
Nimble Therapeutics’ IL23R inhibitor and peptide platform contribute to AbbVie’s peptide therapeutics pipeline.
|
$417.40B |
$230.44
-2.47%
|
|
AZN
AstraZeneca PLC
Peptide therapeutics (e.g., oral GLP-1) represent a peptide-based modality in AZN's pipeline.
|
$282.10B |
$91.75
+0.82%
|
|
NVO
Novo Nordisk A/S
Semaglutide-based peptide therapeutics comprise the company’s differentiated platform (GLP-1 peptides) and core pipeline.
|
$214.81B |
$45.14
-5.23%
|
|
RDY
Dr. Reddy's Laboratories Limited
Peptide therapeutics focus within GLP-1 programs and related peptide APIs/formulations.
|
$11.60B |
$13.66
-1.80%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$7.85B |
$37.90
+9.19%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide) is a peptide-based therapeutic, fitting the peptide therapeutics category.
|
$6.76B |
$106.11
+4.30%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.31B |
$87.93
+2.96%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
DAYBUE (trofinetide) and ACP-101 intranasal carbetocin are peptide therapeutics, supporting a peptide therapeutics business.
|
$3.97B |
$23.82
+1.10%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$3.85B |
$34.59
+0.96%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
GLP-1 collaboration and peptide drug substance/finish capabilities map to Peptide Therapeutics.
|
$3.75B |
$12.20
+2.05%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
Avexitide is a peptide-based GLP-1 receptor antagonist, aligning with the 'Peptide Therapeutics' tag.
|
$1.31B |
$14.85
+1.23%
|
|
OPK
OPKO Health, Inc.
OPK-88006 is a dual GLP-1/glucagon peptide therapeutic (peptide therapeutics).
|
$1.05B |
$1.30
-1.52%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$909.72M |
$31.93
+17.93%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$513.29M |
$3.29
+3.96%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's portfolio includes peptide-based medicines (e.g., desmopressin in ET-600), which fits the Peptide Therapeutics investable theme.
|
$441.42M |
$16.10
-2.19%
|
|
BCYC
Bicycle Therapeutics plc
Bicycle molecules are fully synthetic peptide therapeutics used to target cancer.
|
$438.02M |
$6.75
+6.72%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$424.52M |
$5.14
+6.96%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$394.39M |
$8.01
+4.98%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
CATX
Perspective Therapeutics, Inc.
Pipeline includes peptide-based targeting constructs used to deliver radiopharmaceuticals.
|
$155.21M |
$2.18
+4.31%
|
|
VTGN
VistaGen Therapeutics, Inc.
PH94B and related pherine candidates are peptide-based, aligning with peptide therapeutics.
|
$140.82M |
$4.77
+3.92%
|
|
ELTX
Elicio Therapeutics, Inc.
Peptide components referenced in AMP program, aligning with Peptide Therapeutics.
|
$138.06M |
$8.56
+1.36%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-114 is a GLP-1/GLP-2 dual-agonist peptide program, placing the company in the peptide therapeutics space.
|
$117.15M |
$1.69
+3.37%
|
|
ENTX
Entera Bio Ltd.
Entera Bio develops peptide therapeutics (EB613, EB612, OPK-88006) and related oral peptide programs.
|
$115.53M |
$2.54
+0.40%
|
|
VANI
Vivani Medical, Inc.
Lead programs NPM-115 and NPM-139 are peptide-based GLP-1 receptor agonists, aligning with Peptide Therapeutics.
|
$78.20M |
$1.30
-1.14%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Peptide therapeutics (AI-designed GLP-1 peptides) being developed as internal assets.
|
$54.86M |
N/A
|
|
CUE
Cue Biopharma, Inc.
The platform's peptide-MHC components align with Peptide Therapeutics as a major product modality.
|
$45.72M |
$0.57
-4.03%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$39.77M |
$4.83
+14.73%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 is described as a peptide therapeutic, placing the company in the Peptide Therapeutics category.
|
$34.49M |
$1.50
+1.35%
|
|
PYPD
PolyPid Ltd.
GLP-1 program uses the PLEX platform to deliver long-acting peptide therapeutics (GLP-1) for metabolic diseases.
|
$17.27M |
$3.62
+0.56%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$17.16M |
$1.94
-1.02%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-VA's GDNF-based therapy could be categorized as peptide therapeutics (protein/peptide modality).
|
$14.39M |
$1.14
+4.61%
|
|
BIVI
BioVie Inc.
BIV201 is a continuous-infusion peptide therapy (terlipressin) for liver cirrhosis, mapping to 'Peptide Therapeutics'.
|
$9.76M |
$1.33
+3.09%
|
|
BLRX
BioLineRx Ltd.
Motixafortide is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$7.80M |
$3.39
+4.31%
|
|
BZYR
Burzynski Research Institute, Inc.
Antineoplastons are peptide-based therapeutics; core product category is peptide therapeutics.
|
$5.26M |
$0.04
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Lead asset hCDR1 is a peptide-based therapeutic, fitting the Peptide Therapeutics category.
|
$4.20M |
$0.84
+9.15%
|
|
SILO
Silo Pharma, Inc.
Peptide Therapeutics applies to SPU-16 CNS-homing peptide and related peptide-based delivery/therapeutics platforms.
|
$3.67M |
$0.42
+8.79%
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
Loading company comparison...
Loading industry trends...
Loading research report...
